Eli Lilly and Company (LLY)
| Market Cap | 754.27B |
| Revenue (ttm) | 45.04B |
| Net Income (ttm) | 10.59B |
| Shares Out | 897.99M |
| EPS (ttm) | 11.71 |
| PE Ratio | 71.73 |
| Forward PE | 36.62 |
| Dividend | $6.00 (0.71%) |
| Ex-Dividend Date | Feb 14, 2025 |
| Volume | 10,853,245 |
| Open | 834.50 |
| Previous Close | 734.90 |
| Day's Range | 822.11 - 857.99 |
| 52-Week Range | 677.09 - 972.53 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 1,020.35 (+21.49%) |
| Earnings Date | May 1, 2025 |
About LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]
Financial Performance
In 2024, Eli Lilly's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for LLY stock is "Strong Buy." The 12-month stock price forecast is $1,020.35, which is an increase of 21.49% from the latest price.
News
The Score: UnitedHealth, Netflix, Eli Lilly and More Stocks That Defined the Week
Here are some of the major companies whose stocks moved on the week's news
Eli Lilly Vows to Make Weight-Loss Pill in U.S. as Trump Pushes for Domestic Manufacturing
Eli Lilly plans to make its experimental drug orforglipron in the U.S. after it secures regulatory approval, says CEO Dave Ricks.
Eli Lilly jumps on GLP-1 pill trial success
CNBC's Angelica Peebles joins 'Fast Money' to talk the latest on oral GLP-1 trials.
Eli Lilly's weight-loss pill: What it means for the sector
Eli Lilly surged during Thursday's trading session after promising test results came out of the pharmaceutical company's ongoing weight-loss pill trial. Bernstein US biopharmaceuticals senior analyst ...
Eli Lilly Rallies Over 14%, Notches Best Day Since June 2000 On Oral Weight-Loss Drug Results: Analysts React
Eli Lilly & Co. LLY shares staged their sharpest single-day rally in nearly 25 years Thursday, after unveiling data from a pivotal trial that could cement its leadership in a weight-loss drug market p...
Wall Street Rebounds, Eli Lilly Rallies, UnitedHealth Group Plummets: What's Driving Markets Thursday?
Wall Street saw a rebound in risk appetite on Thursday ahead of the long Easter weekend, as President Donald Trump signaled positive momentum in trade negotiations.
Eli Lilly: Cementing Its GLP-1 Empire With Orforglipron's Promising Phase 3 Results
Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight loss and good tolerability, establishing leadership in obesity treatment. Orforglipron offers advantages over co...
Top Stock Movers Now: UnitedHealth, Nvidia, Eli Lilly and More
The major U.S. equities indexes were mixed at midday Thursday, with the Dow Jones Industrial Average down close to 400 points as UnitedHealth Group (UNH) shares plunged. The tech-heavy Nasdaq and the ...
Lilly's Diabetes Pill Clears Major Trial, Analyst Points To Global Potential
Eli Lilly And Co LLY on Thursday reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and...
Eli Lilly stock surges 15% after clinical trial of weight loss pill shows it works like Ozempic
The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of 16 pounds.
LLY Gains on Weight Loss Pill, AXP Mixed Earnings, DHI Weakness Continues
Eli Lilly (LLY) rallied after it posted positive trial results for its latest weight loss drug. American Express (AXP) had a mixed earnings report but assured Americans are "eating out and enjoying li...
Lilly reports positive phase 3 trial results for GLP-1 pill
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest results from Eli Lilly's efforts to develop a GLP-1 pill.
Lilly confirms date and conference call for first-quarter 2025 financial results announcement
INDIANAPOLIS , April 17, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2025 financial results on May 1, 2025. Lilly will also conduct a conference call that da...
S&P500 and Dow Jones: UnitedHealth Drops 19%, Eli Lilly Jumps on Trial Results
S&P and Nasdaq futures rebound while Dow lags as UnitedHealth sinks 19% on earnings miss; Eli Lilly and Hertz post big premarket gains.
BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics
SAN MATEO, Calif.--(BUSINESS WIRE)--BigHat Biosciences (“BigHat”), a biotechnology company with a machine learning (ML)-guided antibody discovery and development platform, announced a strategic collab...
Eli Lilly stock surges 11% on obesity pill's success in first late-stage trial
Eli Lilly's experimental obesity pill, orforglipron, met its main goals in a closely watched late-stage trial, boosting the company's standing in the fast-growing market for weight loss and diabetes t...
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
Eli Lilly And Co LLY stock is trading higher on Thursday after the U.S. healthcare giant reported topline Phase 3 results from ACHIEVE-1 trial of orforglipron compared to placebo in adults with type 2...
Eli Lilly's weight loss pill succeeds in first late-stage trial - on diabetes patients
CNBC's Angelica Peebles reports on the latest news from Eli Lilly.
Eli Lilly Stock Soars. Why a Weight-Loss Pill Trial Is Giving It a Boost.
The pharmaceuticals company says a trial of the pill showed it was similarly safe to injectable weight-loss drugs.
Eli Lilly's stock soars 13% after reporting positive data from trial of diabetes and weight-loss pill
Eli Lilly & Co.'s Inc.'s stock soared 13% in premarket trade Thursday, after the drug maker reported positive results from a late-stage trial of an oral GLP-1 treatment for Type 2 diabetes.
Lilly pill leads to 7.9% weight loss at 40 weeks in trial
Eli Lilly said on Thursday its experimental pill, orforglipron, led to an average weight loss of 7.9% and lowered blood sugar for overweight patients with type 2 diabetes in a late-stage trial.
Eli Lilly's weight loss pill succeeds in first late-stage trial on diabetes patients
Eli Lilly said its daily obesity pill met the company's goals in the first of several closely watched late-stage trials. The pill helped Type 2 diabetes patients lower their blood sugar and body weigh...
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Orforglipron is the first small molecule GLP-1 to successfully complete a Phase 3 trial, lowering A1C by an average of 1.3% to 1.6% across doses The investigational once-daily oral pill reduced weight...
Eli Lilly's experimental GLP-1 pill met its study goals, helping diabetes patients lower blood sugar and even lose weight
The drug helped lower patients' blood sugar and reduce their weight by an average of 16 pounds.
Eli Lilly Shares Up 13% After Weight Loss Pill Appears As Effective As Ozempic And Mounjaro In Trials
Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily weight loss pill, orforglipron, demonstrated effectiveness consistent with other...